Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | CAB-AXL-ADC |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CAB-AXL-ADC | BA3011 | AXL Antibody 5 | CAB-AXL-ADC is an antibody-drug conjugate comprising a reversible Axl antibody conjugated to monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to Axl-expressing tumor cells, potentially inducing cytotoxicity and tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 827; Journal of Clinical Oncology 2018 36:15_suppl, TPS12126). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03425279 | Phase Ib/II | CAB-AXL-ADC | CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors | Recruiting | USA | 2 |
NCT04681131 | Phase II | CAB-AXL-ADC CAB-AXL-ADC + unspecified PD-1 antibody | CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | Recruiting | USA | 2 |